Jazz Pharmaceuticals

Rylaze

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Jazz Pharmaceuticals

Rylaze HCPCS:

J9021

HCPCS Code Descriptor:

Injection, asparaginase, recombinant, (rylaze), 0.1 mg

Category:

J Code

Rylaze NDCs:

68727-0900-03, 68727-0900-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intramuscular

Rylaze CPT Codes:

Potential CPT administration codes for Rylaze can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

68727-0900-03

About Rylaze:

Rylaze is an Oncology drug manufactured by Jazz Pharmaceuticals and administered via the Intramuscular route of administration. The J Code: J9021 is aligned to the drug Rylaze.

ACCESS PRICING AND MORE BY REGISTERING

J9021 Added Date:

January 1, 2022

J9021 Effective Date:

January 1, 2022

J9021 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Rylaze billing and coding information.
Rylaze patient assistance information can be found through JazzCares at the URL: https://jazzcares.com/
Rylaze prescribing information can be found at the link below:
Information regarding Rylaze’s side effects can be found at MedlinePlus